B. Data substantiating the histopathological diagnosis must be received for review prior 
to participation in the study. If no recent tissue diagnosis is available, the nature of the 
space occupying lesion (e.g. tumor vs. radiation necrosis) will be determined by a 
stereotaxic biopsy of the lesion prior to cell injection. 
C. Pretreatment general physical examination and a comprehensive neurologic 
evaluation. 
D. Renal, hepatic and hematological Evaluation including blood chemistries (uric acid, 
calcium, phosphorus, magnesium, osmolality, SGOT, SGPT, Alkaline Phosphatase, 
LDH, total bilirubin, BUN, creatinine, albumin, total protein, electrolytes, glucose), 
urinalysis with a 24 hr. creatinine clearance, PT, PTT, fibrinogen and a CBC with 
differential and platelets. 
E. Radiological Evaluation. Each patient will undergo an MRI study of the brain without 
and with gadolinium enhancement. CT will be performed with contrast enhancement 
if appropriate. Preliminary decisions regarding the eligibility of the patient for either 
treatment group, and the injections and/or procedures needed for each patient will be 
decided based on these studies. 
F. Immunologic evaluation. 
1. In vitro lymphocyte proliferative responses to mitogens (OKT3, PHA), soluble 
antigens (Diphtheria, Tetanus, Candida albicans), alloantigen and murine 
antigens (PA317 cell). 
2. Cellular phenotype of peripheral blood by dual label FACS analysis (CD3/HLA- 
DR, CD4/CD8, IL-2R) 
3. Isohemagglutinins and quantitative immunoglobulins (A,G,M and E) 
4. Serum for antibody to PA317 cells. 
5. Determination of cytotoxic cell function (NK , LAK and CML as available) 
6. Soluble IL-2R 
7. DTH skin test panel (CMI Multitest or equivalent) 
8. Non-serologic HIV test 
V. Nature of Procedures or Therapeutic agents 
(See schema in Appendix C) 
Recombinant DNA Research, Volume 15 
[807] 
